

1/7

# Changes in contrast-enhancing lesions:




FIG. 1




FIG. 2B

FIG. 2A

3/7





FIG. 3B

FIG. 3A



Trough levels of Zenapax in the current dosing regimen  
(1mg/kg max 100mg) completely saturate CD25 receptor on  
peripheral T cells:




FIG. 5

Parallel to complete blockage of CD25 by Zenapax, also the proliferation of in-vivo activated T cells to IL-2 decreases




FIG. 6B

FIG. 6A

**Upregulation of CTLA-4 on CD4+ T cells  
during administration of Zenapax:**




FIG. 7